Contrave (naltrexone/bupropion) and Wegovy (semaglutide) are brand-name drugs. They’re both prescribed for weight loss in adults. This article explains the main ...

The approval of this second site enhances production capacity, confirming continued patient access to CONTRAVE while reinforcing the company's broader commitment to obesity research and treatment.

BRENTWOOD, Tenn., March 11, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE ® ...

WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation’s 78 million obese ...

Contrave is a combination therapy consisting of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant. Results showed no statistically significant difference in the incidence ...

Breast cancer survivors who lost ≤5% of body weight with diet and exercise experienced greater weight loss, improved function, and less pain with Contrave. Contrave (naltrexone plus buproprion) can ...

Contrave, the weight loss pill that combats food cravings, has launched its first-ever TV commercial-- with audio that features new lyrics to Lesley Gore’s 62-year-old feminist anthem “You Don’t Own ...

In January 2013, small biotechnology firm Orexigen was in the final stages of testing Contrave, a promising new pharmaceutical product for the treatment of obesity. At the time, Orexigen had no ...

BRENTWOOD, Tenn., March 20, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE ® ...

CONTRAVE, approved in the U.S. and marketed in Europe as MYSIMBA, has been studied extensively in both randomized clinical trials and observational settings. The latest analysis builds upon prior ...